콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

M1323

Sigma-Aldrich

Midostaurin hydrate

≥98% (HPLC), solid, kinase inhibitor

동의어(들):

CGP 41251, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methylbenzamide, N-benzoylstaurosporine, PKC-412

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C35H30N4O4 · xH2O
CAS Number:
Molecular Weight:
570.64 (anhydrous basis)
MDL number:
UNSPSC 코드:
12352200
PubChem Substance ID:
NACRES:
NA.77

product name

Midostaurin hydrate, ≥98% (HPLC), solid

분석

≥98% (HPLC)

형태

solid

색상

off-white

solubility

DMSO: >10 mg/mL

저장 온도

−20°C

SMILES string

O.CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)[n@@H]3c4ccccc4c5c6CNC(=O)c6c7c8ccccc8[n@H]2c7c35)N(C)C(=O)c9ccccc9

InChI

1S/C35H30N4O4.H2O/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38;/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40);1H2/t25-,26-,32-,35+;/m1./s1

InChI key

YEKDLUZCCDJYAJ-LJAYRLSQSA-N

생화학적/생리학적 작용

Midostaurin is an inhibitor of tyrosine kinase, protein kinase C, and VEGF. Midostaurin inhibits cell growth and phosphorylation of FLT3, STAT5, and ERK. Midostaurin is a potent inhibitor of a spectrum of FLT3 activation loop mutations.

특징 및 장점

This compound is featured on the PKC page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

픽토그램

Health hazard

신호어

Danger

유해 및 위험 성명서

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

Eyeshields, Gloves, type N95 (US)


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Mahmoud Hallal et al.
BMC cancer, 21(1), 789-789 (2021-07-10)
Despite the introduction of targeted therapies, most patients with myeloid malignancies will not be cured and progress. Genomics is useful to elucidate the mutational landscape but remains limited in the prediction of therapeutic outcome and identification of targets for resistance.
Jin Kawata et al.
Blood cells, molecules & diseases, 54(2), 206-209 (2014-12-04)
Monocytes and neutrophils are activated during disseminated intravascular coagulation. Tissue factor, the main initiator of coagulation, is expressed by monocytes, while elastase is released by neutrophils. This study investigated tissue factor production by peripheral monocytes after stimulation with human neutrophil
Ikuko Omori et al.
Experimental hematology, 52, 56-64 (2017-05-17)
In core-binding factor acute myeloid leukemia (CBF-AML), there have been conflicting reports regarding the status as an unfavorable prognostic factor of mutation in the KIT gene, the significance of which remains unclear. We previously reported that prognoses differ between the
Ee Lin Wong et al.
Nature communications, 10(1), 66-66 (2019-01-10)
Protein-templated fragment ligations have been established as a powerful method for the assembly and detection of optimized protein ligands. Initially developed for reversible ligations, the method has been expanded to irreversible reactions enabling the formation of super-additive fragment combinations. Here
Timea Simon et al.
Nanoscale research letters, 10(1), 466-466 (2015-12-03)
Releasing drug molecules at the targeted location could increase the clinical outcome of a large number of anti-tumor treatments which require low systemic damage and low side effects. Nano-carriers of drugs show great potential for such task due to their

문서

Protein kinase C (PKC) is an AGC kinase that phosphorylates serine and threonine residues in many target proteins.

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.